![DCPRIME_LOGO color cmyk](https://www.glyconet.de/wp-content/uploads/2019/12/DCPRIME_LOGO-color-cmyk-400x70.png)
DCprime is the front-runner in the field of relapse vaccines, a new class of oncology vaccines administered after or in conjunction with standard of care therapy to delay or prevent disease recurrence. Our lead product is a whole-cell-based vaccine addressing blood cancers with a high risk of relapse. We are pursuing similar vaccination approaches for solid tumors. We believe relapse vaccines will improve survival by putting the patient’s immune system back in control.